The National Institute of Allergy and Infectious Diseases (NIAID) announced the commencement of the Phase III trial (NCT04611802) of the Novavax investigational COVID-19 vaccine, in a press release issued on Monday, December 28, 2020. The trial will evaluate the effectiveness, immune response, and safety of a COVID-19 vaccine candidate developed by Novavax, Inc., of Gaithersburg, Maryland, called NVX-CoV2373, and is estimated to complete data collection by March 31, 2021.
{iframe}https://www.genengnews.com/news/novavax-candidate-covid-19-vaccine-moves-into-phase-iii-trial/?utm_medium=newsletter&utm_source=GEN%20Daily%20News%20Highlights&utm_content=01&utm_campaign=GEN%20Daily%20News%20Highlights_20201230&oly_enc_id=1673D8247356B7U{/iframe}